Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The protein encoded by CTAG1B is an antigen that is overexpressed in many cancers but that is also expressed in normal testis. Zusätzlich bieten wir Ihnen Cancer/testis Antigen 1B Kits (3) und Cancer/testis Antigen 1B Proteine (2) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 115 products:
Human Polyclonal CTAG1B Primary Antibody für ELISA, MA - ABIN4265165
Adams, ONeill, Nonaka, Hardin, Chiriboga, Siu, Cruz, Angiulli, Angiulli, Ritter, Holman, Shapiro, Berman, Berner, Shao, Manches, Pan, Venhaus, Hoffman, Jungbluth, Gnjatic, Old, Pavlick, Bhardwaj: Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. in Journal of immunology (Baltimore, Md. : 1950) 2008
Human Polyclonal CTAG1B Primary Antibody für ELISA, WB - ABIN570720
Shan, Lou, Xiao, Zhang, Sun, Gao, Cheng, Wu, Xu, Liu: A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. in Cancer letters 2012
Results support the potential utility of NY-ESO-1, PRAME (zeige PRAME Antikörper), and MAGEA4 (zeige MAGEA4 Antikörper) as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas.
Data suggest that only a small fraction of HLA-A*02:01- (HA)-binding ESO peptides are immunogenic, namely those that have high peptide-binding strength and peptide/HA complex stability. This study involved comparison of in silico-predicted and observed cytotoxic T-lymphocyte recognition of tumor antigen epitopes in melanoma patients and transgenic/knockout mice. (ESO = tumor antigen NY-ESO-1)
These data demonstrate that MAGE (zeige MAGEB10 Antikörper)-A1-, MAGE-A3 (zeige MAGEA3 Antikörper)-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible.
Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated (zeige ZNF654 Antikörper) antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan (zeige SUPT6H Antikörper)-MAGE (zeige MAGEB10 Antikörper) or MAGE-A3 (zeige MAGEA3 Antikörper)/A4 correlated with reduced treatment-failure-free-survival (TFFS).
MAGE (zeige MAGEB10 Antikörper)-A is more highly expressed than NY-ESO-1 in a majority of human malignancies
These cells were used to target a human lung cancer line that expressed NY-ESO-1.
regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites.
CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors.
Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%).
High expression of NY-ESO-1 is associated with Triple-Negative Breast Cancer.
The protein encoded by this gene is an antigen that is overexpressed in many cancers but that is also expressed in normal testis. This gene is found in a duplicated region of the X-chromosome and therefore has a neighboring gene of identical sequence.
New York esophageal squamous cell carcinoma 1
, autoimmunogenic cancer/testis antigen NY-ESO-1
, cancer antigen 3
, cancer/testis antigen 1
, cancer/testis antigen 6.1
, l antigen family member 2